GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Gallbladder and Pancreas/High visceral adiposity and low skeletal muscle mass independently predict the development of acute cholecystitis in patients with gallstones: a retrospective cohort study
40

High visceral adiposity and low skeletal muscle mass independently predict the development of acute cholecystitis in patients with gallstones: a retrospective cohort study

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated December 1, 2025

The retrospective cohort study you are referencing addresses the relationship between body composition and the risk of developing acute cholecystitis in patients with gallstones. The findings highlight that high visceral adiposity (excess visceral fat) and low skeletal muscle mass are independent predictors of acute cholecystitis, emphasizing the role of metabolic and inflammatory factors in disease progression. Below is a detailed breakdown of the study's key insights:

1. Prediction Gap Addressed

  • Traditional risk markers for acute cholecystitis, such as gallstone size or presence alone, are insufficient to predict which patients will progress to inflammation. This study shifts the focus to metabolic and body composition factors, providing a more comprehensive risk stratification.

2. Limits of BMI

  • Body mass index (BMI) is a crude measure of obesity and does not differentiate between types of body tissue (e.g., visceral fat, subcutaneous fat, muscle mass). Therefore, BMI alone cannot accurately predict susceptibility to acute cholecystitis.

3. Role of Visceral Fat

  • Visceral fat is metabolically active and contributes to a chronic pro-inflammatory state. This inflammatory priming makes the gallbladder more susceptible to exaggerated responses to triggers, such as gallstone obstruction, leading to acute cholecystitis.
  • Visceral fat is distinctly associated with disease risk, as opposed to subcutaneous fat, which does not have the same inflammatory properties.

4. Importance of Sarcopenia (Low Skeletal Muscle Mass)

  • Reduced skeletal muscle mass (sarcopenia) is not merely a marker of frailty but actively contributes to disease development. Muscle tissue plays a protective role by providing physiological resilience against inflammatory triggers.
  • Patients with low muscle mass may experience heightened vulnerability to metabolic and inflammatory complications, including acute cholecystitis.

5. Independent Risk Factors

  • Both high visceral fat and low skeletal muscle mass independently increase the likelihood of developing acute cholecystitis. These factors are not dependent on gender, gallstone size, or other traditional risk markers.

6. Gallstones Alone Insufficient

  • The study highlights that gallstones alone are not enough to cause acute cholecystitis. An adverse metabolic background, characterized by visceral adiposity and sarcopenia, is required to trigger the inflammatory process.

7. Systemic Disease Concept

  • Acute cholecystitis should be redefined as a metabolic-inflammatory complication rather than a localized biliary event. This systemic perspective broadens the understanding of the disease, linking it to underlying metabolic syndrome conditions such as hypertension and dyslipidemia.

8. CT-Based Assessment

  • Computed tomography (CT) imaging is a valuable tool for assessing body composition. It enables precise and reproducible measurement of visceral fat and skeletal muscle mass, which are critical for risk stratification.
  • The study emphasizes the use of body composition analysis at the L3 vertebral level, which is a validated standard for representing whole-body composition.

9. Gender Independence

  • The predictive value of visceral fat and muscle mass transcends sex-based differences. Men and women with unfavorable metabolic body composition phenotypes are equally at risk for acute cholecystitis.

10. Preventive Medicine Potential

  • Identifying patients with high visceral fat and low skeletal muscle mass early provides an opportunity for lifestyle interventions, such as tailored diet and exercise programs, to reduce the risk of disease progression.
  • These modifiable risk factors represent actionable targets for preventing acute cholecystitis in at-risk patients.

11. Clinical Paradigm Shift

  • The findings suggest a need to redefine acute cholecystitis as a metabolic-inflammatory complication rather than an isolated biliary obstruction caused by gallstones. This paradigm shift supports a more holistic approach to patient management, focusing on systemic health and body composition.

12. Risk Stratification Tool

  • CT-derived body composition analysis offers a practical and precise method to identify gallstone patients at high risk for acute cholecystitis. This tool can help clinicians prioritize closer monitoring and early intervention for these patients.

13. Peripheral Monitoring Opportunity

  • Patients identified with unfavorable body composition (high visceral fat and low skeletal muscle mass) may benefit from closer clinical surveillance to prevent disease progression and reduce the risk of complications.

14. Inflammatory Priming

  • Pro-inflammatory mediators released by visceral fat sensitize the gallbladder, increasing the likelihood of exaggerated inflammatory responses when gallstones obstruct the bile duct.

15. Metabolic Syndrome Link

  • The study reinforces the connection between acute cholecystitis and metabolic syndrome conditions, such as hypertension, dyslipidemia, and insulin resistance. These systemic factors further contribute to the inflammatory and metabolic background of the disease.

Conclusion:

This retrospective cohort study challenges traditional views of acute cholecystitis as a purely local biliary event and highlights the importance of systemic metabolic and inflammatory factors. High visceral adiposity and low skeletal muscle mass are independent predictors of disease development, providing actionable insights for early risk stratification, preventive interventions, and a shift in clinical management toward addressing the broader metabolic-inflammatory context of acute cholecystitis.

Related Q&A

41

LAMS for EUS-guided drainage of pancreatic fluid collections

Lumen-apposing metal stents (LAMS) have emerged as a highly effective tool for endoscopic ultrasound (EUS)-guided drainage of pancreatic fluid collections (PFCs), such as pseudocysts and walled-off necrosis. This...

42

EUS-guided GJ in acute pancreatitis related Gastric Outlet obstruction

Endoscopic Ultrasound-Guided Gastrojejunostomy (EUS-GJ) is an innovative, minimally invasive procedure that has gained traction as a treatment for gastric outlet obstruction (GOO) due to duodenal stenosis caused by...

43

EUS-guided ethanol injections of small pancreatic NET

Endoscopic ultrasonography-guided ethanol injection (EUS-EI) is emerging as a promising, minimally invasive treatment for small pancreatic neuroendocrine tumors (PNENs), particularly for patients seeking alternatives to surgery. This approach...

44

Surveillance of Primary Sclerosing Cholangitis - EASL Guideline

Surveillance for Primary Sclerosing Cholangitis (PSC) is critical due to the high risk of hepatobiliary complications, including cholangiocarcinoma (CCA), gallbladder cancer, and liver failure, all of which significantly...

45

Optimal timing for LAMS removal after EUS-guided drainage of PFC

The optimal timing for lumen-apposing metal stent (LAMS) removal after EUS-guided drainage of pancreatic fluid collections (PFCs) does not necessarily depend on a fixed timeline, such as early...

46

Portal versus peripheral circulating tumor cells in PDAC

The study you referenced investigates the differences between portal and peripheral circulating tumor cells (CTCs) in pancreatic ductal adenocarcinoma (PDAC) and their prognostic value. Here’s a detailed breakdown...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer